<DOC>
	<DOC>NCT01269684</DOC>
	<brief_summary>The purpose of this study is to investigate safety and tolerability of an immediate conversion from Tacrolimus to everolimus in stable renal allograft recipients. Interest in developing CNI-free regimens using other agents such as the proliferation signal inhibitor everolimus.</brief_summary>
	<brief_title>Immediate Conversion From Tacrolimus to Everolimus in Stable Maintenance Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Inclusion criteria Primary or secondary renal transplantation in the past 1236 months. Current immunosuppressive therapy consisting of Tacrolimus together with MMF +/corticosteroids. Moderately impaired renal function Exclusion criteria Multiorgan recipients or previous transplantation with an organ other than a kidney. Acute rejection episodes in the last 6 months. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Kidney</keyword>
	<keyword>renal</keyword>
	<keyword>transplantation</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>everolimus</keyword>
	<keyword>stable allograft recipients</keyword>
</DOC>